Imvaq is an innovative biotechnology company developing novel immuno-oncologics to treat metastatic cancer. Based on the research of Imvaq's distinguished scientific founders at Memorial Sloan Kettering Cancer Center, one of the leading clinical and R&D cancer hospitals in the world, we are focused on creating therapeutic products that synergize with a patient's own immune system to eradicate the cancer, locally and abscopally.